CN104902876B - 新型药物组合物 - Google Patents

新型药物组合物 Download PDF

Info

Publication number
CN104902876B
CN104902876B CN201380062796.7A CN201380062796A CN104902876B CN 104902876 B CN104902876 B CN 104902876B CN 201380062796 A CN201380062796 A CN 201380062796A CN 104902876 B CN104902876 B CN 104902876B
Authority
CN
China
Prior art keywords
suitably
compound
cancer
inhibitors
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380062796.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN104902876A (zh
Inventor
G·坎贝尔
F·亨利柯兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Novartis Pharma AG
Glaxo Group Ltd
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50828398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104902876(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Priority to CN201711343653.XA priority Critical patent/CN107970214A/zh
Publication of CN104902876A publication Critical patent/CN104902876A/zh
Application granted granted Critical
Publication of CN104902876B publication Critical patent/CN104902876B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
CN201380062796.7A 2012-11-30 2013-11-26 新型药物组合物 Active CN104902876B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711343653.XA CN107970214A (zh) 2012-11-30 2013-11-26 新型药物组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261731597P 2012-11-30 2012-11-30
US61/731,597 2012-11-30
PCT/US2013/071816 WO2014085371A1 (en) 2012-11-30 2013-11-26 Novel pharmaceutical composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201711343653.XA Division CN107970214A (zh) 2012-11-30 2013-11-26 新型药物组合物

Publications (2)

Publication Number Publication Date
CN104902876A CN104902876A (zh) 2015-09-09
CN104902876B true CN104902876B (zh) 2018-01-19

Family

ID=50828398

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201711343653.XA Pending CN107970214A (zh) 2012-11-30 2013-11-26 新型药物组合物
CN201380062796.7A Active CN104902876B (zh) 2012-11-30 2013-11-26 新型药物组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201711343653.XA Pending CN107970214A (zh) 2012-11-30 2013-11-26 新型药物组合物

Country Status (28)

Country Link
US (2) US20150328320A1 (enExample)
EP (2) EP2925299B1 (enExample)
JP (1) JP6232443B2 (enExample)
KR (1) KR102206432B1 (enExample)
CN (2) CN107970214A (enExample)
AR (1) AR093648A1 (enExample)
AU (1) AU2013352369B2 (enExample)
BR (1) BR112015012111A8 (enExample)
CA (1) CA2891346A1 (enExample)
CL (1) CL2015001459A1 (enExample)
EA (2) EA028246B1 (enExample)
ES (1) ES2686730T3 (enExample)
IL (3) IL300664A (enExample)
IN (1) IN2015DN04094A (enExample)
MA (1) MA38121A1 (enExample)
MX (1) MX2015006867A (enExample)
MY (1) MY170427A (enExample)
NZ (1) NZ628395A (enExample)
PE (1) PE20151024A1 (enExample)
PH (1) PH12015501168A1 (enExample)
PL (1) PL2925299T3 (enExample)
PT (1) PT2925299T (enExample)
SG (1) SG11201503688SA (enExample)
TN (1) TN2015000198A1 (enExample)
TW (2) TW201831187A (enExample)
UY (1) UY35157A (enExample)
WO (1) WO2014085371A1 (enExample)
ZA (1) ZA201503346B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102293907B1 (ko) * 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
US20200178569A1 (en) * 2016-04-29 2020-06-11 Alvin Kershman Method of Coating an Edible Thermoplastic Pet Chew
TW201818936A (zh) 2016-11-25 2018-06-01 大陸商江蘇恆瑞醫藥股份有限公司 一種吡啶酮類衍生物醫藥組成物及其製備方法
KR102230721B1 (ko) * 2019-02-01 2021-03-22 주식회사 오스코텍 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법
JP2022554148A (ja) * 2019-10-22 2022-12-28 ケミストリーアールエックス 表皮及び真皮の過形成を治療するための方法
AU2022414970A1 (en) * 2021-12-15 2024-06-27 Sillajen, Inc. Pharmaceutical compositions comprising modified beta-cyclodextrins
KR20250008895A (ko) * 2022-05-12 2025-01-16 주식회사 지뉴브 안정한 액상 제약 제제
WO2025132408A2 (en) 2023-12-21 2025-06-26 Synthon B.V. Solvates of trametinib

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
CN1872055A (zh) * 2005-06-01 2006-12-06 李�杰 适合儿童应用的阿莫西林与盐酸氨溴索的复方制剂及其处方和制备方法
CN101352419A (zh) * 2007-07-26 2009-01-28 天津药物研究院 一种醋溴茶碱无糖型颗粒剂及其制备方法
CN102600132A (zh) * 2012-03-13 2012-07-25 齐鲁制药有限公司 一种含氨磺必利的口服制剂
CN102626394A (zh) * 2012-03-15 2012-08-08 合肥科大生物技术有限公司 一种精氨酸布洛芬颗粒剂及其制备方法
CN102655753A (zh) * 2009-10-16 2012-09-05 葛兰素史密丝克莱恩有限责任公司 组合药

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
RU2364596C2 (ru) * 2004-06-11 2009-08-20 Джапан Тобакко Инк. ПРОИЗВОДНЫЕ 5-АМИНО-2,4,7-ТРИОКСО-3,4,7,8-ТЕТРАГИДРО-2Н-ПИРИДО[2,3-d] ПИРИМИДИНА, ОБЛАДАЮЩИЕ ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТЬЮ
ES2408216T3 (es) * 2004-12-07 2013-06-19 Onyx Therapeutics, Inc. Composición para la inhibición del proteasoma
EP2581078B1 (en) * 2005-10-26 2014-12-10 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US20080176946A1 (en) * 2007-01-16 2008-07-24 Bipar Sciences, Inc. Formulations for cancer treatment
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
KR101478779B1 (ko) * 2007-11-22 2015-01-05 에스케이케미칼주식회사 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법
JP5940078B2 (ja) 2010-11-11 2016-06-29 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ アリールアミノアルコール−置換２，３−ジヒドロイミダゾ［１，２−ｃ］キノリン
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
US20130023531A1 (en) 2011-01-27 2013-01-24 Boehringer Ingelheim International Gmbh Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
ES2590778T3 (es) 2011-02-28 2016-11-23 Calitor Sciences, Llc Compuestos de quinolina sustituida
AU2012238589B2 (en) * 2011-04-07 2017-02-16 Bayer Intellectual Property Gmbh Imidazopyridazines as Akt kinase inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
CN1872055A (zh) * 2005-06-01 2006-12-06 李�杰 适合儿童应用的阿莫西林与盐酸氨溴索的复方制剂及其处方和制备方法
CN101352419A (zh) * 2007-07-26 2009-01-28 天津药物研究院 一种醋溴茶碱无糖型颗粒剂及其制备方法
CN102655753A (zh) * 2009-10-16 2012-09-05 葛兰素史密丝克莱恩有限责任公司 组合药
CN102600132A (zh) * 2012-03-13 2012-07-25 齐鲁制药有限公司 一种含氨磺必利的口服制剂
CN102626394A (zh) * 2012-03-15 2012-08-08 合肥科大生物技术有限公司 一种精氨酸布洛芬颗粒剂及其制备方法

Also Published As

Publication number Publication date
EA201791411A1 (ru) 2018-03-30
CL2015001459A1 (es) 2015-12-18
BR112015012111A2 (pt) 2017-07-11
JP2016501874A (ja) 2016-01-21
SG11201503688SA (en) 2015-06-29
AR093648A1 (es) 2015-06-17
EP2925299A1 (en) 2015-10-07
EA028246B1 (ru) 2017-10-31
NZ628395A (en) 2016-10-28
MA38121A1 (fr) 2016-10-31
EP3400933A1 (en) 2018-11-14
AU2013352369B2 (en) 2016-07-28
TN2015000198A1 (en) 2016-10-03
TW201434468A (zh) 2014-09-16
UY35157A (es) 2014-06-30
PH12015501168A1 (en) 2015-08-10
BR112015012111A8 (pt) 2018-01-23
TW201831187A (zh) 2018-09-01
IL238971A0 (en) 2015-07-30
CN104902876A (zh) 2015-09-09
ES2686730T3 (es) 2018-10-19
IL266415A (en) 2019-06-30
IL300664A (en) 2023-04-01
WO2014085371A1 (en) 2014-06-05
MX2015006867A (es) 2015-10-05
MY170427A (en) 2019-07-31
IL266415B2 (en) 2024-03-01
US20170189408A1 (en) 2017-07-06
EA201591047A1 (ru) 2015-11-30
KR20150091352A (ko) 2015-08-10
US20150328320A1 (en) 2015-11-19
HK1209047A1 (en) 2016-03-24
IL238971B (en) 2019-05-30
IN2015DN04094A (enExample) 2015-10-09
JP6232443B2 (ja) 2017-11-15
CN107970214A (zh) 2018-05-01
AU2013352369A1 (en) 2015-05-28
KR102206432B1 (ko) 2021-01-22
EP2925299A4 (en) 2016-06-29
CA2891346A1 (en) 2014-06-05
PE20151024A1 (es) 2015-07-27
ZA201503346B (en) 2016-01-27
IL266415B1 (en) 2023-11-01
EP2925299B1 (en) 2018-06-06
PT2925299T (pt) 2018-10-16
PL2925299T3 (pl) 2018-11-30

Similar Documents

Publication Publication Date Title
CN104902876B (zh) 新型药物组合物
CN103998041B (zh) 药物组合物
CN106061481A (zh) 用于治疗癌症的雄激素受体抑制剂与akt抑制剂的组合
AU2025242246A1 (en) Novel pharmaceutical composition
CN105792825A (zh) 组合
HK1259834A1 (en) Novel pharmaceutical trametinib composition
RU2779429C2 (ru) Новая фармацевтическая композиция
CN104902896A (zh) 组合
HK1209047B (en) Novel pharmaceutical composition
CN106456642A (zh) 含btk抑制剂与akt抑制剂的组合

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20200907

Address after: Basel, Switzerland

Patentee after: NOVARTIS AG

Address before: Basel, Switzerland

Patentee before: NOVARTIS PHARMA AG

Effective date of registration: 20200907

Address after: Basel, Switzerland

Patentee after: NOVARTIS PHARMA AG

Address before: British Meader Sykes

Patentee before: GLAXO Group Ltd.

Effective date of registration: 20200907

Address after: British Meader Sykes

Patentee after: GLAXO Group Ltd.

Address before: Delaware, USA

Patentee before: GLAXOSMITHKLINE LLC